Early Transcranial Doppler Goal Directed Therapy After Cardiac Arrest: a Pilot Study
- Conditions
- Cerebral LesionCardiac ArrestIschemic EncephalopathyIschemic Reperfusion Injury
- Interventions
- Other: MAP between 65 and 85 mmHgOther: MAP increased to optimize cerebral blood flow
- Registration Number
- NCT04000334
- Lead Sponsor
- Centre Hospitalier le Mans
- Brief Summary
Hypoxic-ischaemic brain injury (HIBI) is the main cause of death in patients who are comatose after resuscitation from cardiac arrest. Current guidelines recommend to target a mean arterial pressure (MAP) above 65 mmHg to achieve an adequate organ perfusion. Moreover, after cardiac arrest, cerebral autoregulation is dysregulated and cerebral blood flow (CBF) depends on the MAP. A higher blood pressure target could improve cerebral perfusion and HIBI. Transcranial Doppler (TCD) is a non-invasive method to study CBF and its variations induced by MAP.
The aim of this study is to test the feasibility of an early-goal directed hemodynamic management with TCD during the first 12 hours after return of spontaneous circulation (ROSC).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 20
- Patients admitted in the Intensive Care Unit (ICU) under mechanical ventilation with a Glasgow Coma Scale ≤ 8/15 after in- or out-of-hospital cardiac arrest
- Mean arterial pressure between 65 and 85 mmHg with or without vasopressor support
- Age < 18 years old
- No flow (time between cardiac arrest and the beginning of cardiac massage) > 15 minutes or unknown
- Low flow ((time between cardiac arrest and ROSC: return of spontaneous circulation)> 60 minutes
- Time between ROSC and inclusion > 12 hours
- Transcranial doppler unavailable
- Cardiac arrythmia
- Patient under extracorporeal life support before inclusion or at risk of being referred for assistance due to cardiogenic shock with high dose of vasopressors before inclusion (MAP < 65 mmHg with norepinephrine or epinephrine > 1 µg/kg/min or dobutamine > 10 µg/kg/min)
- Severe cardiac dysfunction defined by left ventricular ejection fraction < 20% or aortic Velocity Time Integral (VTI: measured with trans-thoracic echocardiography) < 14 cm with dobutamine > 10µg/kg/min
- Patient under Extracorporeal Membrane Oxygenation (ECMO) for Acute Respiratory Distress Syndrome (ARDS) before inclusion
- Cardiac arrest secondary to brain injury such as stroke, subarachnoid hemorrhage or traumatic brain injury
- Hemorrhagic shock
- Any acute pathology that requires strict blood pressure control (aortic dissection, stroke, cardiogenic pulmonary edema with high blood pressure)
- Decision of withdrawing or withholding life sustaining treatment before inclusion or considered during the first 12 hours of ICU management
- Patient with a modified Rankin scale (MRS) 4 or 5 prior to resuscitation
- Pregnancy or lactation
- Patients already enrolled in another clinical study on cardiac arrest
- Patients with judicial protection
- No social security coverage
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Normal cerebral perfusion (group B) MAP between 65 and 85 mmHg Normal cerebral perfusion will be defined by a normal TCD at inclusion (t0) when two of the three measured values are normal using the following thresholds: Vm \> 30 cm/s, Vd \> 20 cm/s, PI \< 1.4. Cerebral hypoperfusion (group A) MAP increased to optimize cerebral blood flow Cerebral hypoperfusion will be defined by an abnormal TCD at inclusion (t0) when two of the three measured values are abnormal using the following thresholds: Vm \< 30 cm/s, Vd \< 20 cm/s, PI \> 1.4.
- Primary Outcome Measures
Name Time Method Proportion of patients in whom the transcranial doppler goal directed therapy will result in a modification of MAP targets In the first hour after inclusion Proportion of patients in whom transcranial doppler goal directed therapy will result in a modification of MAP targets.
- Secondary Outcome Measures
Name Time Method Cerebral oxygenation modifications induced by increasing MAP At the 6th, 12th, 24th, 48th and 72nd hour after inclusion Bulb jugular venous oxygen saturation modifications induced by increasing MAP at 90-100 mmHg and 100-110 mmHg.
28 day survival 28 days after inclusion Proportion of patients alive 28 days after inclusion
Cerebral blood flow modifications induced by increasing MAP At the 6th, 12th, 24th, 48th and 72nd hour after inclusion Transcranial doppler data modifications induced by increasing MAP to 90-100 mmHg and 100-110 mmHg.
Measure of the degree of disability in the activities of daily living of the included patients 90 days after inclusion Modified Rankin scale (MRS) 90 days after inclusion. The scale runs from 0-6, running from perfect health without symptoms to death.
0 - No symptoms.
1. - No significant disability. Able to carry out all usual activities, despite some symptoms.
2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
3. - Moderate disability. Requires some help, but able to walk unassisted.
4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
6. - Dead.Undesirable events induced by increasing MAP At the 72nd hour after inclusion Number of neurologic events defined by intracranial hematoma or brain death
Plasmatic concentrations of Neuron Specific Enolase At the 72nd hour after inclusion Neuron Specific Enolase (NSE) plasmatic concentrations at H+72h after cardiac arrest
90 days survival 90 days after inclusion Proportion of patients alive 90 days after inclusion
Trial Locations
- Locations (1)
Centre Hospitalier Le Mans
🇫🇷Le Mans, France